Transcenta Therapeutics and WuXi Biologics Team Up to Accelerate Commercialization of HiCB Technology

Transcenta Therapeutics, headquartered in China, is a clinical-stage biopharmaceutical company with a pipeline of over ten therapeutic antibody candidates and expertise in biologics discovery, translational research, clinical, and process development. The company is teaming up with WuXi Biologics to accelerate commercialization of HiCB technology.